NIDCR Prospective Observational or Biomarker Validation Study Cooperative Agreement (U01 Clinical Trial Not Allowed)
National Institutes of Health
Want a reminder before this closes?
We'll email you 3 days before the deadline. One email, then we stop.
Free. Verify your email, then we send one reminder only.
- Posted
- Oct 23, 2025
- Amount
- $500,000
- Closes
- Jul 5, 2029 (in 1014 days)
Similar opportunities open now
- NIAID Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required)Same funderOpenNational Institutes of HealthCloses Jul 2029
- NIH Brain Development Cohorts (NBDC) and Population Assessment of Tobacco and Health (PATH) Study Biospecimen Access (X01 Clinical Trial Not Allowed)Same funderOpenNational Institutes of HealthCloses Apr 2029
- NIAID Investigator Initiated Program Project Applications (P01 Clinical Trial Not Allowed)Same funderOpenNational Institutes of HealthCloses May 2029
- Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01 Clinical Trial Not Allowed)Same funderOpenNational Institutes of HealthCloses Oct 14, 2026 (in 19 days)
- NIH Collaborative International Research Project (Parent PF5 Clinical Trial Optional)Same funderOpenNational Institutes of HealthCloses May 2029
Classification and identifiers
- Solicitation number
- PAR-27-058
- Assistance listing (CFDA)
- 93.121
Amount
$500,000
Who can apply
Local government agencies and Public colleges and universities can all apply here. Check the eligibility details below to see if your organization fits.
Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
About this opportunity
This Notice of Funding Opportunity (NOFO) will support, through the cooperative agreement mechanism, investigator-initiated observational studies or biomarker validation studies that require prospective collection of data/biospecimens or continued analysis of data/biospecimens.